Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

NCT04828057 is registered in ClinicalTrials.gov with Santen Pharmaceutical (Taiwan) Co., LTD as lead sponsor.

NCT NCT04828057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04828057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Lead sponsor
Santen Pharmaceutical (Taiwan) Co., LTD
Phase
Observational
Overall status
Completed
Start date
September 1, 2021
Completion date
August 24, 2022
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular surface disease, primary open angle glaucoma